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Systematic Development of Sandwich Immunoassays
for the Plasma Secretome
Ragna S. Ha¨ussler, Annika Bendes, MariaJesus Iglesias, Laura Sanchez-Rivera,
Tea Dodig-Crnkovi´c, Sanna Bystro¨m, Claudia Fredolini, Elin Birgersson, Matilda Dale,
Fredrik Edfors, Linn Fagerberg, Johan Rockberg, Hanna Tegel, Mathias Uhle´n,
Ulrika Qundos, and Jochen M. Schwenk*
The plasma proteome oﬀers a clinically useful window into human health.
Recent advances from highly multiplexed assays now call for appropriate
pipelines to validate individual candidates. Here, a workﬂow is developed to
build dual binder sandwich immunoassays (SIA) and for proteins predicted to
be secreted into plasma. Utilizing suspension bead arrays, 1800 unique
antibody pairs are ﬁrst screened against 209 proteins with recombinant
proteins as well as EDTA plasma. Employing 624 unique antibodies,
dilution-dependent curves in plasma and concentration-dependent curves of
full-length proteins for 102 (49%) of the targets are obtained. For 22 protein
assays, the longitudinal, interindividual, and technical performance is
determined in a set of plasma samples collected from 18 healthy subjects
every third month over 1 year. Finally, 14 of these assays are compared with
with SIAs composed of other binders, proximity extension assays, and
aﬃnity-free targeted mass spectrometry. The workﬂow provides a multiplexed
approach to screen for SIA pairs that suggests using at least three antibodies
per target. This design is applicable for a wider range of targets of the plasma
proteome, and the assays can be applied for discovery but also to validate
emerging candidates derived from other platforms.
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1. Introduction
There is a continuously great interest
in increasing our understanding about
those proteins that are expected to be
present in blood and found outside the
intracellular space, and to apply appro-
priate tools to discover and validate these
in a given study context.[1] Such eﬀorts
preferably target the proteins that are ac-
tively secreted in comparison to those
that appear in blood due to leakage,
cell death, or cellular turnaround. To-
day, the human secretome can be de-
ﬁned by bioinformatics tools annotating
our genome based on sequences found
in the protein-encoding regions.[2] Using
an updated annotation,[3] more than 2600
proteins were deﬁned as the secretome.
Of these only about 600 proteins are
predicted to be actively secreted to the
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blood while another 1000 proteins were localized to the mem-
brane and/or the intracellular space.[3]
The technically measurable content of the human plasma pro-
teome currently contains nearly 5000 proteins when combining
the eﬀorts conducted withmass spectrometry (MS) as well as im-
munoassay platforms.[4] MS alone detected about 3500 plasma
proteins of which a third ( 1230) were annotated as being se-
creted. It has been shown that untargeted and MS-based ap-
proaches contribute to this list with primarily cellular compo-
nents. Immunoassays on the other hand are often more sen-
sitive to detect low abundant proteins, deﬁned as those below
1 ngmL–1, and these are often linked to cytokines and inﬂamma-
tion processes.[5] However, and upon excluding the recent large-
scale aptamer studies, only about one-third of the currently anno-
tated 2600 proteins of the secretome[3] can bemeasured in plasma
using other immunoassay-based methods. Plasma proﬁling ef-
forts using shotgun MS, such as those by Mann and co-workers,
detected 1200 proteins[6] in plasma. The latest versions of multi-
plexed immunoassay, not included in the above stated collection
of plasma proteins, used 5000 aptamers to proﬁle 5000 donors,
as shown by Emilsson et al.[7]
Here, we present a complementary approach to multiplexed
assay systems and systematically build SIAs for the proteins of
the plasma secretome. Our eﬀorts are centered around the fea-
sibility of screening and validating the antibody (Ab) pairs for
a variety of proteins at the same time, rather than focusing on
only a few shortlisted targets. This pipeline is built in a way to in-
clude all secreted proteins, and hence oﬀers an opportunity to de-
velop assays to detect those 1370 secreted proteins that cannot
be detected by MS today, for example, IL6. Hence it expands on
previous workﬂows that primarily work on selected candidates.[8]
Our approach was accelerated by accessing a large resource of
Abs from the Human Protein Atlas (HPA) and full-length pro-
teins generated within the Human Secretome Project[3] (HSP)
within the Wallenberg Centre for Protein Research (WCPR). The
study was conducted on a multiplexed bead array platform and
combined the assessment of Ab pairs using both recombinant
proteins and EDTA plasma. We did not preselect the secreted
proteins based on other prior knowledge or particular interest
but rather availability of reagents to conduct this proof-of-concept
study from screening, via validation to the analysis of longitudi-
nal samples.
2. Experimental Section
2.1. Plasma Samples
All methods were conducted according to the Declaration of
Helsinki, which establishes the regulations and guidelines for re-
search project execution for human health.
The screening for SIA pairs was conducted on pools of anony-
mous donors and did not require sensitive personal information
about the donors. The research did not include any type of inter-
vention, surgery, or treatment. The Ethical Review Board in Upp-
sala (Dnr 2009/019) deemed that this research was not subjected
to formal ethical review and approval. Samples of human K2
EDTA plasma were purchased on two occasions from Sera Lab-
oratories International Ltd (HMPLEDTA2, now part of BioIVT,
Signiﬁcance Statement
There is a substantial interest inmonitoringhumanhealth
via the analysis of accessible samplematerial such as blood
plasma. In addition to eﬀorts focusingonmeasuringmore
proteins in a larger number of samples,wepresent a comple-
mentary pipeline that allows validating thenovel candidates in
a systematic andquantitativemanner. Since sandwich-based
assays are oneof themost important test concepts for clinical
care,wedevelopedourworkﬂow tobuild SIAs for several se-
cretedproteins in parallel.Wealsopresent the challenges and
solutionswhendeveloping thesedual binder assays andweput
forwarddecision criteria for prioritizing antibodypairs. Further-
more,we evaluate theperformanceof the SIA assays in longi-
tudinal samples, supporting thenotion that protein in plasma
are stable over timewhenbeing analyzed in consecutively col-
lected samples. Lastly, we alsoprovide adirect comparisonof
our datawith other types of proteomicsmeasurements, hence
give valuable insightswhen translating assays fromone tech-
nology to another, providematching antibodypairs to develop
of assays toward clinical utility or for the adaptation toother
immunoassay-based technologies.
West Sussex, UK), who collects samples under IRB-approved pro-
tocols in use at their FDA-licensed donor centers with written
informed consent obtained from all donors. The pools of plasma
samples were generated by the supplier from mixing plasma
from donors of which 50% were females.
The selected SIA pairs were then used to study samples col-
lected from 18 subjects over a 1-year time period. Each subject
consenting to participate in the longitudinal Swedish SCAPIS
SciLifeLab Wellness Proﬁling (S3WP) program (ethical approval
Dnr 407–15) donated plasma every third month. Within this
study, a total of 101 healthy subjects were recruited from the
ongoing Swedish CArdioPulmonary bioImage Study (SCAPIS),
which is a prospective observational study of randomly selected
subjects aged 50–64 years from the general Swedish population.
All participants have been extensively phenotyped before enter-
ing the S3WP program.[9] Blood plasma samples were collected
using 6 mL EDTA tubes (Vacuette, 456243) and centrifuged at
3000 rpm at room temperature immediately after sample collec-
tion. Then, the plasma was transferred to 0.5 mL tubes (Sarstedt,
72.730.003) and was frozen within 20 min past centrifugation.
From the 101 participants, we analyzed a gender matched sub-
set of plasma samples collected from nine male (mean age 57.6)
and nine female donors (mean age 57.3). The SIA pair targeting
EFEMP1 was conducted on a diﬀerent selection of 18 subjects,
due to the available sample volume. For this sample selection
again nine male (mean age 56.6) and nine female donors (mean
age 59) were chosen.
2.2. Target Selection and Generation
Protein targets for the secretome were selected according
to availability of full-length proteins within the HSP and
Abs from the HPA as well as considering the recombinant
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protein concentration. HPA Abs needed to have a concentration
of > 0.05 mg mL–1 for being chosen as capture antibody (ca-
pAb) and of > 0.1 mg mL–1 for being considered as detection
Ab (detAb).
2.3. Production and Puriﬁcation of Secreted Proteins
Secreted proteins were deﬁned based on data in the Uniprot
database as well as signal peptide and transmembrane region
predictions made for the transcripts in the Ensembl database.
A generic expression cassette, based on the CMV promoter and
with an N-terminal CD33 signal peptide for secretion of all pro-
duced proteins and a C-terminal human protein C tag for puriﬁ-
cation, was used. All secreted proteins were produced by using
the transient Icosagen Cell Factory system with CHOEBNALT-85
cells and theQMCFTechnology (IcosagenCell FactoryOU¨, Tartu,
Estonia). Cells were maintained in a 50:50 mixture of 293 SFM
II (Gibco, 11686029) and CD CHO medium (Gibco, 10743001)
with a supplement of 6 mM GlutaMAX (Gibco, 35050061)
and 10 mL per l HT supplement 50X (Gibco, 41065012) at
37 °C on an orbital shaker. A total of six million cells were
transfected by electroporation. The transfected cells were added
to fresh prewarmed 20 mL medium containing penicillin–
streptomycin (Sigma–Aldrich, P4333-100ML) in 125 mL shak-
ing ﬂasks (Sigma–Aldrich, CLS431143-50EA) and cultivated in a
fed batch cultivation for 13 days. Forty-eight hour after transfec-
tion cells were diluted to 400 000 cells mL–1 with fresh medium.
Successful transfection and protein secretion were determined
6 days after transfection by performing Western Blots. Positive
screened samples were initiated to production by the addition of
20% CHO CD EﬃcientFeed B (Thermo Fisher, A1024001) and a
temperature shift to 30 °C. A second feed of 10%was added at day
9 after transfection. The supernatant was clariﬁed by centrifuga-
tion and serine-protease inhibitor was then added. For puriﬁca-
tion, 1 mL of an in house developed anti protein C aﬃnity matrix
was used. The harvest sample was ﬁltrated into the matrix and
CaCl2 was added to a ﬁnal concentration of 2 mm. The tube with
sample and matrix was then incubated in a cold room overnight.
After packing the matrix in a column, it was washed with equili-
bration buﬀer (20 mm Tris, 100 mm NaCl, 2 mm CaCl2, pH 7.5)
and thereafter a ﬁlter was placed on top of the matrix and the col-
umn was placed on ASPEC 271 or 274 liquid handlers (Gilson
Inc.). After an additional washing step (20 mm Tris, 1 m NaCl,
2 mm CaCl2, pH 7.5) the protein was eluted using a mild elu-
tion with EDTA (20 mm Tris, 100 mmNaCl, 2 mm EDTA, pH 7.5)
prior a buﬀer exchange into 1× PBS. After desalting, the protein
concentration was determined (Abs). Each puriﬁed protein was
identiﬁed by MS/MS and the purity was analyzed using SDS-
PAGE and western blot. Primary Ab for western blotting was a
rabbit Anti-C tag polyclonal (GTX18591, Genetex). Glycosylation
patterns of the puriﬁed proteins were also analyzed using SDS-
PAGE.
2.4. Antibodies
Overall, 624 Abs targeting 209 unique secreted human proteins,
as well as 11 assay speciﬁc controls were included. Majority of
the Abs used polyclonal rabbit Abs generated within HPA project
(www.proteinatlas.org).[10] The assay speciﬁc controls included
aﬃnity puriﬁed rabbit IgG (P120-301, Bethyl laboratories) in
order to control for background binding to rabbit IgG molecules
and a blocked bare bead (without coupled Ab) to monitor
background binding to the beads. These two will from now on
be referred to as “assay controls.” In addition, a set of ten mon-
oclonal mouse Abs from BioSystems International,[11] targeting
plasma proteins commonly enriched by immuno-capture assays
were included.[12] These will be referred to as “internal controls.”
All Abs used are listed in (Table S1, Supporting Information).
2.5. Coupling of Antibodies to Beads
Bead arrays were created as previously described.[13] Antibod-
ies were diluted to 17.5 µg mL–1 in 100 µL 0.1 m 2[N-
Morpholino]ethanesulfonic acid (MES)-buﬀer (M2933, Sigma–
Aldrich), pH 4.5, using a pipetting robot (TECAN EVO150),
and then coupled to carboxylated color-coded magnetic beads
(MagPlex-C, Luminex Corp). In short, 500 000 beads per dis-
tinct color-coded region (ID) were located into one wells of 96-
well microtiter plates (Greiner BioOne) respectively and washed
with 80 µL 0.1 m NaH2PO4 (phosphate buﬀer) pH 6.2 (S3139,
Sigma Life Science) with a plate washer/dispenser (EL406,
Biotek) on magnet. Subsequently, 50 µL phosphate buﬀer was
added manually. Activation buﬀer consisting of 10 mg mL–1
1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) (C1100,
ProteoChem) and 10 mg mL–1 sulfo-N-hydroxysulfosuccinimide
(Sulfo-NHS) (24510, Thermo-Fisher Scientiﬁc) in phosphate
buﬀer were subsequently added to the beads, resulting in 0.5 mg
EDC and 0.5 mg Sulfo-NHS per well. Activation buﬀer and
beads were incubated for 20 min at 650 rpm at room temper-
ature and washed two times with 100 µL 0.1 m MES. The pre-
diluted Abs were added to the activated beads and incubated for
2 h at 650 rpm at room temperature. After incubation, the Ab-
coupled beads were washed three times in 100 µL 1 × PBS (09-
9400, Medicago), 0.05% Tween20 (BP337, Fisher Bioreagents)
(PBS-T), and re-suspended in 50 µL storage buﬀer (Blocking
Reagent for ELISA, 11 112 589 001, Roche Diagnostics) supple-
mented with ProClin (4812-U, Sigma–Aldrich). The individual
bead IDs were pooled together after overnight blocking at 4 °C,
creating six bead stocks containing 65–95 diﬀerent kinds of Ab-
coupled beads, including ten additional control Abs each, coupled
to unique bead IDs. The coupling eﬃciency of the Ab-coupled
beads was tested using R-Phycoerythrin-conjugated (RPE) goat
anti-rabbit IgG (111-116-144, Jackson ImmunoResearch) and
RPE-conjugated goat anti-mouse IgG (115-116-146, Jackson Im-
munoResearch). One hundredmicroliter RPE-conjugatedAbs di-
luted to 0.5 µg mL–1 in PBS-T were added to 5 µL Ab-coupled
bead stock in diﬀerent wells, followed by incubation for 20 min
at 650 rpm at room temperature. After incubation, wells were
washed three times with 100 µL PBS-T before analyzed on a
Flexmap 3D instrument (Luminex corp.). Signals for the cou-
pling eﬃciency were reported in terms of median ﬂuorescence
intensities (MFI). Coupled beads were regarded as a failed cou-
pling if the signals obtained were lower than 2 × SD than the
mean value for the bead stock. In case of failed coupling, a re-
coupling of this speciﬁc Ab was performed.
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2.6. Biotinylation of Detection Antibodies
Antibodies used as detAbs were biotinylated as described
previously.[14] In short, 2 µg of each Ab was diluted in 30 µL
PBS-T and then incubated with 5 µL protein A-coated magnetic
beads (30 mg mL–1, Dynabeads, 10002D, Invitrogen) for 30 min,
room temperature, 650 rpm. After incubation, the Ab-coupled
beads were washed three times in 100 µL PBS-T before label-
ing the Abs with a 150 × molar excess of EZ-Link-NHS-PEG4 –
Biotin (21329, Thermo Scientiﬁc) dissolved in DMSO (276855,
Sigma–Aldrich) for 30 min, room temperature, 650 rpm. The
beads were thenwashed three times in 100 µL PBS-T. The labeled
Abs were dissociated from the beads by adding 15 µL 0.2 m ac-
etate (97064-482, VWR), pH 3.2 (elution buﬀer) to the wells and
incubated for 2 min at room temperature, while mixing gently.
The supernatants were collected using a magnet and transferred
into individual tubes. To buﬀer the solution, 5 µL of 0.5 m Tris-
base (T6066, Sigma–Aldrich), pH 8, was added to each eluate.
Subsequently, 5 µL PBS-T were added to each tube and the la-
beled Abs were stored at 4 °C with an estimated concentration of
0.072 µg µL–1.
The biotinylation eﬃciency was tested by diluting the labeled
Ab to 1 µg mL–1 in PBS-T, and adding 25 µL of prediluted la-
beled Ab to 2 µL of donkey anti-rabbit IgG (711-005-152, Jackson
ImmunoResearch) coupled beads followed by incubation for 1 h
at 650 rpm at room temperature. After incubation, wells were
washed three times with 100 µL PBS-T. Subsequently, 50 µL of
a 1:750 dilution of RPE-labeled streptavidin (SA10044, Invitro-
gen) were added and incubated for 20 min, room temperature,
650 rpm. After incubation, wells were washed three times with
100 µL PBS-T, before analyzed on a Flexmap 3D instrument (Lu-
minex corp.). Abs with signals 50× above background were con-
sidered successfully biotinylated.
2.7. Assay Procedure and Read Out
For assay performance, two diﬀerent batches of commercially
available human K2 EDTA mixed gender plasma pool (HM-
PLEDTA2, Seralab) were serially diluted in plasma dilution buﬀer
to cover a dilution range of 1:4 till 1:3000 in seven stepswith equal
dilution. The ﬁrst screening round used a diﬀerent plasma batch
then the rest of the experiments. The plasma dilution buﬀer
consisted of 1 × PBS with 0.5% (w/v) polyvinylalcohol (P8136,
Sigma–Aldrich), 0.8% (w/v) polyvinylpyrrolidone (PVP360,
Sigma Life Science), 0.1% casein (C5890, Sigma Life Science),
and supplemented with 0.5 mgmL–1 rabbit IgG. A spike-in serial
dilution of standard proteins in plasma dilution buﬀer was per-
formed, covering a concentration range of 1 µgmL–1 to 1 ngmL–1.
Blanks of both assay buﬀer and plasma dilution buﬀer were
added and will be referred to as “blank sample.”
The pre-diluted plasma samples and the pre-diluted protein
standards (45 µL) were transferred to 5 µL bead stock in an as-
say plate (Greiner 384-well assay plate) using a liquid handler
(SELMA, CyBio) before overnight incubation at 650 rpm at room
temperature.
After incubation, the beads were washed three times with
60 µL PBS-T. The biotinylated detAbs were diluted to 1 µg mL–1
in PBS-T. Subsequently the beads were incubated for 1.5 h at
room temperature at 650 rpm with 25 µL of the respective pre-
diluted detAb. Beads were washed three times with 60 µL PBS-T
before incubation with 50 µL of a 1:750 dilution of RPE-labeled
streptavidin for 20 min at room temperature at 650 rpm. Finally,
beads were washed three times with 60 µL PBS-T, before they
were re-suspended in 60 µl PBS-T and analyzed on a Flexmap 3D
instrument (Luminex corp.). Binding events were displayed as
MFI where at least 50 beads per bead ID were counted.
Each assay plate represents one experimental assay run com-
bined of two 96-well plates containing serial dilutions of human
plasma pool as well as two 96-well plates containing serial diluted
standard curves of the proteins investigated. Protein and plasma
dilution series for the same detAbs were placed on the same 384-
plate (Figure S1, Supporting Information). Additionally, interfer-
ing plate-eﬀects were avoided by running all measurements for
one target protein on the same 384-plate. In total, twenty-six 384-
well plates were measured, containing between two and 15 pro-
teins each. A detailed plate layout can be found in Figure S1,
Supporting Information.
2.8. Assay Optimization and Validation
The assay design wasmodiﬁed and optimized each time between
two phases. After the screening phase, the buﬀer matrix for the
protein standards was changed by adding 1%BSA (A7030, Sigma
Life Science) to achieve a higher matrix complexity. Additionally,
the length of the dilution curves for the protein standard was ex-
tended from a seven-step concentration to a 14-step concentra-
tion series in triplicates covering a range of 1 µgmL–1 to 1 pgmL–1
when evaluating the reproducibility of the assays. The dilution
points for plasma were also adapted to the signals achieved dur-
ing screening, to both cover a broader measuring range, but also
to be more suitable for the obtained signals. Thus a seven-step
dilution series of human EDTA plasma pool with a consistent
step size of three starting between 1:2 and 1:36 in plasma di-
lution buﬀer was conducted for each Ab pair. The suspension
bead arrays (SBAs) for the selection process were composed with
diﬀerent capAbs for further technical investigations in order to
exclude additional oﬀ-target interactions. The remaining target
proteins were grouped as sets of ﬁve into SBAs containing 8–18
Abs, based on their alphabetical order. Each set of SBAs was sup-
plemented with the assay controls, to record possible binding to
the beads. For protein quantiﬁcation and application of the SIA
pairs, assays were run on a longitudinal sample set as well as an
eight-step protein concentration series, covering the optimized
signal range, and measured in triplicates.
2.9. Selection Criteria
After selecting protein targets for the secretome according to
availability, and HPA Abs both according to availability and
concentration (>0.05 mg mL–1 for being chosen either as capAb
or detAb), Ab pairs had passed several selection rounds in
order to achieve reliably functioning Ab pairs. This process was
divided into three phases: an initial screening phase, which
was sub-divided into two rounds, a selection phase and an
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application phase. For all phases, MFIs were registered for each
bead ID and sample.
Annotation after screening phase was performed manually.
Hereby, Ab pairs were grouped based on their functionality into
four diﬀerent categories: 1) dilution-dependent curves with pro-
tein and plasma, 2) dilution-dependent curves with protein only,
3) dilution-dependent curves with plasma only, and 4) no dilution
dependent curves. This was assessed according to the shape and
concentration dependency of the curve for the expected pair.
Pairs being processed to be further tested had to be assigned
to group 1 as well as reach a maximum signal intensity of at
least 150 MFI in order to report only signals above an average
background. To limit the number of total assays, one detAb was
chosen per protein. For the detAbs, any concentration dependent
binding for the other Ab-coupled beads in the SBA, such as the
internal controls, were used as exclusion criteria. As additional
criteria, a pair was chosen upon showing the widest range of
detectable concentrations of proteins in buﬀer and plasma, an
overall lower background level in antigen-free samples, and in-
dications about possible interferences or oﬀ-target recognition of
other captured proteins. Finally, the available Ab volumewas con-
sidered for the polyclonal binders.
After an additional testing round of the chosen pairs in trip-
licates of plasma dilution and protein standard dilution the CV
was determined for each dilution point averaging it across all di-
lution steps to ﬁnd the best performing Ab pairs (see Figure 4A–
D). As cut-oﬀ criteria a CV of 3.3% in protein assays and 4.3%
in plasma assays was deﬁned. In addition, pairs requiring more
than 12.5 µL sample (representing a 1:4 sample dilution) or more
than 150 ng (=3000 ng mL–1 as the highest concentration point)
per assay were excluded in respect to sample and protein con-
sumption. For the technical replicates during the selection phase
the upper limit of quantiﬁcation (ULOQ), lower limit of quan-
tiﬁcation (LLOQ), LOD, and 50% eﬀective dose (ED50) were cal-
culated. One pair per target was prioritized and the calculated
ED50 point was chosen as the optimal sample dilution point. In
cases of similar performance, Ab pairs generated toward diﬀerent
binding regions were prioritized. Also, Ab pairs with the superior
LLOQ were preferred (see Table S2, Supporting Information).
Before processing the remaining Ab pairs into the ﬁnal appli-
cation phase and measuring them on a selection of 72 samples
from a healthy longitudinal cohort, diﬀerent Ab pairs were
combined into possible duplex combinations with the same de-
termined optimal sample dilution. The ﬁnal concentration mea-
sured for each sample was calculated by transforming the mea-
suredMFI signal intensities into a concentration value according
to the dilution curve obtained from the 5-parametic ﬁt and mul-
tiplying it with the applied dilution factor of the sample (see Fig-
ure 5A–D). Samples with protein concentration below the calcu-
lated LLOQ or above ULOQwere excluded from further analysis.
2.10. Orthogonal Assays
For orthogonal comparison of the targets, the overlap of the cho-
sen 21 targets was correlated with data achieved by two indepen-
dent experimental setups for the same sample selection: 1) a re-
cently published targeted MS approach[15] and 2) multiplex prox-
imity extension assays (Olink Bioscience, Uppsala Sweden).[16]
Figure 1. Setup for screening for SIA pairs. For capturing, Abs (1) were im-
mobilized ontomagnetic color-coded beads (2) and combined into sets of
suspension bead arrays (3). A dilution series of EDTA plasma (4a) and pro-
tein standard (4b) was performed. Beads were then combined with either
EDTA plasma or protein standard (5). After washing oﬀ unbound proteins,
the captured proteins were detected via biotinylated Abs (6 and 7). The
readout occurred by the addition of a streptavidin-ﬂuorophore and using
the Luminex systems (8).
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For the targeted MS approach 432 samples were prepared
semi-automatically using the Bravo liquid handler and subse-
quently measured using a combination of Ultimate 3000 binary
RS nano LC system (Thermo Scientiﬁc) with an EASY-Spray ion
source connected to an online Q Exactive HF (Thermo Scientiﬁc)
MS. All plasma sampleswere stored lyophilized and resuspended
by the autosampler. Sample analysis was performed using a pre-
viously developed PRMmethod. Each full MS scan at 60 000 res-
olution (AGC target 3e6, mass range 350–1600m/z and injection
time 110 ms) was followed by 20 MS/MS scans at 30 000 reso-
lution (AGC target 2e5, NCE 27, isolation window 1.5 m/z, and
injection time 55 ms), which were deﬁned by a scheduled (2 min
windows) PRM isolation list that contained 174 paired light and
heavy peptide precursors (n (peptides) = 87) from 55 QPrESTs
directed toward 52 human proteins. The raw MS-ﬁles from all
study samples were processed in Skyline (version 3.7) and ana-
lyzed in R (version 3.4.1) for protein quantiﬁcation.
For some of the measured plasma proteins, additional vali-
dation was achieved by using multiplex proximity extension as-
says. Each kit contained a microtiter plate measuring 92 protein
biomarkers in up to 90 samples. Each well contained 96 pairs of
DNA-labeled Ab probes. Samples were incubated in the presence
of proximity Ab pairs taggedwithDNA reportermolecules.When
the Ab pairs bound to their corresponding antigens, the corre-
sponding DNA tails form an amplicon by proximity extension,
which can be quantiﬁed by high-throughput real-time PCR.[16,17]
Tominimize inter- and intra-run variation, the data were normal-
ized using both an internal control (extension control) and an
interplate control, and then transformed using a predetermined
correction factor. The preprocessed data were provided in the ar-
bitrary unit Normalized Protein eXpression (NPX) on a log2 scale.
A high NPX presented high protein concentration.[17]
2.11. Data Analysis (Data Processing, Classiﬁcation, and Curve
Fitting)
Data analysis and visualizations were performed within R
(www.rproject.org, version R 3.5.1).[18] To assess reproducibil-
ity for overlapping targets between the two screening rounds,
corresponding MFI values were log transformed and corre-
lated using Pearson correlation with R2 values. To assess the
binding region for capAbs and detAbs on the screened pro-
teins, the immunogens aminoacidic sequence for each HPA was
mapped to the sequences of the corresponding canonical protein
(www.proteinatlas.org). Protein sequences were exported from
the Uniprot data base (release 2018 07).[19]
To evaluate the performance of Ab pairs during the selection
phase, data were log10 transformed and visualized as dilution
curves.
Data were log10 transformed and a ﬁve-parametric log-logistic
model was applied for the dilution curves in the application
phase.[20] LOD levels were calculated as 3× SD of the blank sam-
ple above the average blank signal, LLOQwas deﬁned as 10× SD
of the blank sample above the average blank signal,[21] ULOQwas
deﬁned as the averaged signal of the highest protein standard
concentration point minus its SD. ED50 was calculated using the
drc package.[20] In instances in which the SD was small, leading
to negative output of the ﬁve-parametric ﬁt for the LOD values,
the MFI values for the blank were manually increased by adding
2 AU. No signiﬁcant eﬀect on the calculated protein concentra-
tions for those targets could be observed.
Assay CVs within the selection phase were calculated between
the duplicated dilutions steps of the plasma protein curve, while
during the later application phase the assay variance was calcu-
lated with the triplicated sample pool. During this phase two ad-
ditional layers of variance were calculated: variances for each pro-
tein between the 18 individuals (per visit), which will be referred
to as interindividual CV, as well as the average variance between
the 18 subjects over the course of 1 year (four samples per sub-
ject), which will be referred to as intra-individual variance. For vi-
sualizing diﬀerent layers of variance (assay variance, interindivid-
ual variance, and intraindividual variance), CVs were calculated
and ternary plots were generated using the ggtern package.[22]
Euclidian distances for investigating the personal plasma pro-
ﬁle diﬀerences were calculated using the daisy function in the
R package “cluster”.[23] Prior to the calculation, the data under-
went an outlier removal process, meaning values above ULOQ
and below LLOQ as well as NA values were removed from the
data set. The data were then scaled before computing pairwise
dissimilarities and Euclidean distances. Additionally, Pearson
distance for interindividual and intraindividual correlation was
calculated, using the R2 value.
For the correlation plots between diﬀerent types of data were
used: MS data (fmol µL–1) were mean-centered and both MS data
as well as SIA data (ng mL–1) were log-transformed with the bi-
nary logarithm, while PEA data (NPX values) were used as pro-
vided and correlated using Pearson correlation with R2 values.
3. Results
We aimed to develop a multiplexed workﬂow (Figure 1) to search
and select for Ab pairs for the analysis of proteins secreted into
Figure 2. Workﬂow. A set of 209 protein targets, covered by 624 Abs and resulting in 2170 corresponding Ab pairs were selected and screened on dilution
series of both, recombinant proteins as well as an EDTA plasma pool. For some proteins, more than one protein construct was tested, while some Ab
pairs were duplicated (§ numbers include those). All pairs were assessed manually for concentration dependent curves in both plasma and protein.
1084 pairs (168 proteins) showed a concentration dependent curve for the protein standard of which 361 unique pairs additionally detected protein in
a concentration dependent manner in plasma. For these 361 pairs, corresponding to 102 unique proteins, an additional signal intensity cutoﬀ criteria
of > 150 MFI was implemented. Out of the initial 361 pairs, we used 221 for further studies in triplicates, which corresponded to 70 out of the 102
initial proteins. Results of the triplicate measurements were assessed, implementing technical aspects for exclusion, (e.g., assay reproducibility, LOD
in protein assays, sensitivity toward the target protein in plasma, CV), but also additional criteria with respect to the available Ab volume, sample, and
protein consumption. By this, 32 pairs targeting 22 proteins were left for further analysis. One pair per protein was chosen for validation according to
LLOQ, using the ED50 point as the optimal sample dilution point. Finally, the selected 22 pairs were applied as SIAs for the determination of protein
levels on a longitudinal plasma sample set (n = 72). For 21 pairs, a protein quantiﬁcation was possible, of which 14 could be compared orthogonally
with data from targeted plasma mass spectrometry analysis (MS) or solution-based proximity extension assays (PEA).
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Figure 3. Correlation for ANGPTL3 (detAb: HPA038097) in screening assays. For each detAb, correlation for all capAbs was performed both for protein
standard (top) and plasma (bottom) dilution. Correlation between overlapping targets of the two screening rounds was calculated using log10 trans-
formed MFI data and Pearson correlation with R2 values. Conﬁdence interval for each pair was calculated in R based on a linear model and highlighted
in the plots.
Table 1. Annotation of antibody pairs determined during the screening
rounds.
#1 #2 Total
Number of pairs 1118 (100%) 1052 (100%) 1791 (100%)
Passed protein assays only 336 (30%) 331 (31%) 664 (37%)
Passed plasma assays only 77 (7%) 96 (9%) 173 (10%)
Passed both samples types 170 (15%) 247 (23%) 361 (20%)
Failed 535 (48%) 378 (36%) 593 (33%)
human plasma (Figure 2). We combined the capabilities of the
SBA technology with the resource of HSP’s full-length proteins
and Abs generated by the HPA project and investigated > 200
proteins as well as 1800 possible Ab pairs. The project was
designed to be conducted in the following stages: 1) screening
for possible Ab pairs in dilution series of protein and plasma
samples, 2) preselection of suitable pairs after assessing their ap-
parent functionality, 3) annotation of preselected Ab pairs accord-
ing to their binding area, 4) selection of Ab pairs for further inves-
tigations focusing on technical aspects, 5) preparation of duplex
sets for plasma analysis, 6) quantiﬁcation of plasma protein levels
in a longitudinal sample set, and 7) compare these results with
data from independent, orthogonal methods.
3.1. Screening for Antibody Pairs
3.1.1. Experimental Study Design
We studied a total of 209 full length proteins and used a pool of
EDTA plasma samples to determine and to develop SIAs. The
screening was conducted in two rounds of 109 and 124 proteins,
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Table 2. Distribution of binding regions.
Capture region Detection region Tested Ab pairs Percentage of tested Passed Ab pairs Percentage of passed
N-terminal N-terminal 176 10% 29 16%
N-terminal Middle 77 4% 10 13%
N-terminal C-terminal 104 6% 6 6%
Middle N-terminal 85 5% 12 14%
Middle Middle 434 24% 48 11%
Middle C-terminal 179 10% 21 12%
C-terminal N-terminal 98 5% 7 7%
C-terminal Middle 165 9% 29 18%
C-terminal C-terminal 473 26% 61 13%
where we aimed at replicating the ﬁndings from the ﬁrst round
by also including all targets with an apparent functional Ab pair,
corresponding to 23 proteins, in screening round 2. For ﬁnding
Abs from the HPA resource, we chose a concentration cutoﬀ of
0.05 mg mL–1 for protein capture, and found 624 Abs for all pro-
teins (see Table S1, Supporting Information). This meant that as-
says could be developed using an average of three to four Abs
per protein, and the coverage ranged from one to eight HPA Abs
per protein (see Figure S2, Supporting Information). We chose to
combine 49–88 diﬀerent Abs in one SBA. Among all 624 Abs, we
selected those with concentrations 0.1 mg mL–1 and an avail-
able volume 0.5 mL as detection agents. This means that an
average of two to three Abs were biotinylated per target protein,
and the coverage ranged from one to seven detAbs. Hence, a total
of 2170 Ab pairs were investigated, of which 1791 were unique.
The screening rounds were conducted by grouping the pro-
teins into sets of six per assay batch and SBA. Each protein assay
contained an SBA of the corresponding Abs as well as those tar-
geting the other ﬁve proteins. Each SBA also contained control
beads to judge the unspeciﬁc binding to the beads, and was dis-
tributed into two 384-well plates. The total number of assays per
protein was deﬁned by the number of available detAbs, and each
detAbwas used in eight concentration levels of proteins and eight
dilution steps for EDTA plasma. In total, we conducted 9264 as-
says and generated 553 056 data points for the 209 proteins.
3.1.2. Reproducibility of Screening Results
To assess the reproducibility between the two performed screen-
ing rounds, 23 proteins corresponding to 200 unique and target-
matched Ab pairs were included in the second screenings. The
assay conditions were in terms of dilution factor, number of di-
lution steps, and the starting concentration for both plasma and
protein maintained in the second screening. Out of the 23 tar-
gets, assay pairs for 16 targets ( 70%) revealed reproducible bind-
ing curves for both protein and EDTA plasma, as exempliﬁed by
ANGPTL3 shown in Figure 3. For each target, at least one unique
Ab pair had a correlation of R2 > 0.92 for the protein as well as
R2 > 0.86 in plasma. In total, 73% of all overlapping pairs had
R2 > 0.95 in protein assays, while 59%were> 0.95 in assays with
plasma. The pairs toward the additional six targets were regarded
as reproduced for the protein assay; however, the detectability
in plasma was lower compared to the ﬁrst screening. A higher
degree of reproducibility was observed for targets that provided
signal intensity levels further away from the apparent LOD. Addi-
tionally, using two diﬀerent batches of EDTA plasma pool for the
two screening rounds could have inﬂuenced the reproducibility.
3.2. Preselection of Antibody Pairs
From the generated data, binding curves were manually anno-
tated for plasma and protein in order to classify each Ab pair and
select those for further optimization as illustrated in Figure 2.
A summary of the outcome of the selection process is shown
in Table 1. To select pairs based on their apparent functionality,
we assessed the shape and concentration dependency of the
curve for the expected Ab pair with the used assay conditions.
We also considered all other Abs (oﬀ-target Ab pairs) included
in each SBA as a background measure and noted if unexpected
pairs were found in either the protein or plasma samples. All
possible pairs were then assigned to one of the following four
classiﬁcations according to their functionality:
1) Dilution and concentration dependent curves plasma and
protein, respectively
2) Concentration dependent curves with protein only
3) Dilution dependent curves with plasma only
4) No dilution or concentration dependent curves
As also summarized in Supplementary Figure 3, from almost
1800 possible Ab pairs there were 170 from screening #1 and 247
from screening #2 that detected their target in plasma and recom-
binant protein. In total, 361 unique pairs were consequently an-
notated as “passed” and considered for further assessment and
optimization. The remaining pairs did not show a concentration
dependent curve for both sample types and may require further
time to develop, hence were not considered for further sample
analysis.
3.3. Annotation of Preselected Antibody Pairs
As an additional assessment, we investigated the location on
the protein to which the pairs of capAb and detAb bound their
respective target. We chose to approximate the binding areas
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Figure 4. A–D) Dilution curves during selection phase for ANGPTL3, CHIT1, CPA1 and FGF21 in protein standard and plasma. During selection phase,
dilution curves for all targets including all capAbs corresponding to one detAb were plotted to evaluate the performance of the diﬀerent pairs. The signals
above background (>150 MFI) are indicated by a horizontal dotted line. Exemplary dilution curves for ANGPTL3 (A), CHIT1 (B), CPA1 (C), and FGF21
(D) in recombinant protein standard (left) and EDTA plasma (right) are shown.
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Figure 4. Continued.
of the Abs by using their immunogens aminoacidic sequences
(22–151 residues in length) and mapping these to the sequences
of the canonical protein. Here, we segmented each protein
sequence into three equally long parts (N-terminal, middle, and
C-terminal). As shown inTable 2, there were generallymore pairs
for constellations that targeted the same region, which was due to
using Abs for capture and detection, generated toward an epitope
located in the same region. Also, there were more pairs targeting
the middle and C-terminal region than in combination with
N-terminal binders. Considering the success rate for building
SIAs from the screening assessment criteria, we found that
on average about 12% of all pre-selected pairs passed these.
A slightly higher success rate of 16% was found for purely
N-terminal targeted Ab pairs as well as pairs built with a capAb
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Table 3. Determination of secreted proteins in plasma (n = 72).
Protein
LOD
[ng mL–1]
LLOQ
[ng mL–1]
ULOQ
[ng mL–1]
ED50
[ng mL–1]
Sample
dilution
Determined [c]
[ng mL–1]
Literature average
[c] [ng mL–1]
Commercial SIA kit
range [c] [ng mL–1]
AFM 0.2 1.2 1400 89.1 1/400 23 740 ± 7110 75 350[34] 0.078–5
ANGPTL3b) 0.01 0.05 4 0.5 1/300 149 ± 65 723[28] 0.031–2
APOA4 0.06 1.1 740 173.2 1/3000 32 960 ± 23 170 197 500[34] 0.25–16
CCL16b) 0.1 0.4 16 2.1 1/30 71 ± 23 11[31] 0.008–0.5
CD5La) 0.006 0.19 100 18.6 1/30 441 ± 132 5530[35] 0.156–10
CFHR5a),b) 0.1 0.4 73 7.1 1/20 160 ± 37 1660[36] 0.156–10
CFP 1.3 14 1000 234.7 1/10 1520 ± 467 25 000[37] 15.63–1000
CHIT1a),b) 0.002 0.01 39 1.2 1/20 65 ± 69 21.4[25] 0.156–10
CPA1b) 0.00003 0.008 16 0.7 1/30 47 ± 24 908.5[4] 0.65–150
CPN2 0.5 2.7 910 63.1 1/1000 51 840 ± 13 920 55 915.4[4] 1.56–100
EFEMP1 6.6 28 1100 97.2 1/5 381 ± 107 10.5[38] 1.56–100
EFNA1 0.004 0.01 1.2 0.2 1/40 7.8 ± 2.4 7.7[4] 0.156–10
FGF21 0.00002 0.0002 0.4 0.1 1/10 0.3 ± 0.2 0.5[24] 0.031–2
FGL1 0.06 0.2 910 47.3 1/10 613 ± 216 23.3[4] 0.156–10
GNAS 0.003 0.01 3.6 0.7 1/10 2 ± 0.9 5.4[4] 0.312–20
HRG 0.3 1.1 23 6.7 1/1000 15 120 ± 2070 100 000[39] 0.469–30
HSP90B1b) 0.03 0.1 4.4 1.4 1/300 972 ± 728 464[4] 0.156–10
IGFBP2 0.02 0.2 800 6.3 1/40 379 ± 276 310[31] 0.063–4
INHBC 0.02 0.1 1100 79.0 1/40 386 ± 194 56.2[4] 0.016–1
NPPA 0.003 0.008 24 0.4 1/10 9.1 ± 4.5 0.06[29] 0.016–1
SPON2a),b) 0.2 0.6 48 5.5 1/20 68 ± 25 23.6[40] 0.078–5
a)Measured in serum; b)Measured in duplex assays.
and detAb targeting the C-terminal and middle, respectively
(18%). The lowest success rate of6% was related to preselected
binder pairs targeting each one of the termini. Out of the total
1791 pairs, there were 138 pairs passing the selection process of
which both Abs targeted the same region.
3.4. Selection of Antibody Pairs
In a third step, we aimed at further shortlisting those preselected
Ab pairs. As a primary criterion, the generated level of intensity
(reported as MFI) was chosen as an additional cutoﬀ in order to
report signals that were ﬁve times above an average background
level determined by the assay controls (MFI = 30 AU). Those
pairs that did not reach a maximal MFI from the protein assay
curves of MFI > 150 were therefore excluded. Out of the initial
361 pairs, we used 221 for further studies, which corresponded
to 70 of the 102 initial proteins.
The subsequent investigations focused on technical aspects
such as assay reproducibility, the apparent LOD using proteins
assays, as well as sensitivity of detecting the target protein in
plasma samples. All analyses were conducted using triplicates of
protein concentration series. To further resemble a sample ma-
trix of higher complexity, the buﬀer used for technical assess-
ment of protein assays was supplemented by adding 1% BSA.
BSA was not added to the buﬀer for plasma analysis. For each
protein, one detAb was prioritized to limit the number of total
assays. In cases where several detAbs were available after prese-
lection, additional criteria for prioritizationwere applied: Ab pairs
with the widest range of detectable concentrations of proteins in
buﬀer and plasma, an overall lower background level in antigen-
free samples, and no previous indications about possible inter-
ferences or oﬀtarget recognition of other captured proteins. The
latter was possible to be observed during the screening phase,
where ﬁve other proteins were also tested in parallel, as each SBA
was built with a common set of 49–88 Abs covering six proteins.
For the detAbs, any concentration dependent binding for other
Ab-coupled beads in the SBA, such as the internal controls, were
added as exclusion criteria. Finally, the available Ab volume was
considered for the polyclonal binders.
For the selection processes of Ab pairs, target proteins were
regrouped into new sets of ﬁve protein targets. Concentration
of the proteins and the dilution of EDTA plasma were adapted
for each individual target according to the data obtained during
the screening. Each assay therefore covered a broader range
of concentrations in order to determine the optimal dilution
point for plasma analysis. Exempliﬁed for SIA pairs targeting
ANGPTL3, CHIT1, CPA1, and FGF21, shown in Figure 4A–D,
protein detection was speciﬁc and accompanied by only very
minor increase in signals from other beads. When analyzing
plasma, we found that background signals from other Abs arose
when using plasma at a lower dilution than 1:50 dilutions. Still,
at a plasma dilution of 1:12, the intended signals were ﬁvefold
above any other binder pair.
Out of the 221 pairs targeting 70 proteins, we found 43 pairs
for 27 proteins suitable for further analysis according to the
criteria stated above. To further ﬁnd the best performing Ab
pairs for one protein, we determined the CV by calculating the
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Figure 5. A–D) Protein concentration for ANGPTL3, CHIT1, CPA1, and FGF21 in application phase (n = 72). To quantify protein concentration in
longitudinal samples during application phase, a 5-parametric log-logistic model was applied for the dilution curves of the protein standard for ANGPTL3
(A), CHIT1 (B), CPA1 (C), and FGF21 (D). Additionally, LOD, LLOQ (red dashed lines), ULOQ (blue dashed lines), and ED50 (grey dashed lines)
were calculated. Pooled samples (orange) were plotted onto the curve. If several capAbs were included in the assays, the selected pair is highlighted
with “*.”
variance for each dilution point using log2 data, and then using
the average across all dilutions within this range for ranking the
pairs. As shown in the annotation table (Table S2, Supporting In-
formation), the average CV using log-transformed data was 2.2%
for plasma and 2% for protein standard and ranged from 0.4% to
7% in plasma and 0.9% to 4.8% in protein. A set of 10 Ab pairs
showing averaged CVs for > 3.3% in protein assays and > 4.3%
in plasma assays was excluded from further analysis. Prior to
choosing the ﬁnal set of Ab pairs for plasma proﬁling, sample
and protein consumption was considered. Plasma assays requir-
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Figure 6. Ternary plot to visualize assay and sample variance. Assay vari-
ance was correlated with the inter-individual variance as well as the intra-
ndividual variance using a ternary plot. Assay variance was calculated
between the triplicated sample pool, inte-individual CV was deﬁned as the
variance of each protein between 18 individuals per visit, while the intrain-
dividual CV is the average variance between the 18 subjects per target over
the course of one year. Proteins showing a low assay variance were high-
lighted in green (0-10%) and blue (10-20%). Data for ANGPTL3 showed
an elevated technical variance, which places this protein among ones high-
lighted in red (assay variance between 20% and 30%).
ingmore samples> 12.5 µL per assay (representing a 1:4 sample
dilution) and amounts of proteins exceeding 150 ng
(3000 ng mL–1 as the highest concentration point) were de-
prioritized. This led to 32 Ab pairs against 22 proteins for further
plasma analysis.
3.5. Preparation of Ab Pairs for Duplexed Plasma Analysis
To achieve a more eﬃcient sample analysis, the data from each
protein and plasma dilution curve were compared. The concen-
tration levels for an ED50 were calculated and chosen as the op-
timal sample dilution point. In order to ﬁnd the optimal plasma
dilution factor per target protein, one Ab pair and ED50 had to be
chosen per protein. In cases of similar performance assessment
characteristics (see above), Ab pairs generated toward diﬀerent
binding regions were prioritized. Also, Ab pairs with the supe-
rior LLOQ were preferred as these generally allow us to cover
a broader range of protein levels. To attempt for a higher pro-
tein throughput, improve time- and cost-eﬃciency of the assays,
and also reduce sample consumption, we searched for possible
combinations of diﬀerent Ab pairs with the same optimal sample
dilution and limited ourselves to assays in duplex. Some com-
binations were directly excluded due to previously observed in-
compatibility, so that four duplex assays and 14 single-plex assays
remained, as shown in in Table 3. We did not ﬁnd a direct rela-
tion between the protein concentration values found in the liter-
ature and the degree of sample dilution (Figure S4, Supporting
Information).
3.6. Analysis of Protein Levels in a Longitudinal Sample Set
Finally, the selected 22 Ab pairs were used in SIAs for the deter-
mination of protein levels in a collection of longitudinal plasma
samples. The study set was built of 18 individuals that donated
plasma every third month over 1 year. Using the 72 samples col-
lected from four visits, each subject allowed us on the one hand
to determine the technical suitability of the selected Ab pairs for
analysis of proteins and on the other hand, we could illustrate
how protein levels of individuals vary longitudinally and between
sample collections.
We quantiﬁed 21 of the tested 22 proteins and listed the per-
formance of the assays in Table 3, where the stated protein
concentration for each target was calculated from the average
concentration over all samples per donor. The protein levels de-
termined here generally agreed well with those found in the lit-
erature (see Figure S5, Supporting Information). The standard
curves from the new assays are shown in Figure 5A–D and relate
to those introduced in Figure 4A–D.
In Figure 6, we further compared three layers of variance: tech-
nical precision, interindividual diﬀerences, as well as longitudi-
nal changes. The ternary plot showed that several proteins, such
as CHIT1, CPA1, or FGF21, were stable over time and could
be accurately measured, while diﬀering in levels between the
donors. The data for ANGPTL3, however, were less conclusive
due to an elevated technical variance (CV> 21%, using raw data).
In addition to variance analysis, we used distances from clus-
tering analysis to compare the interindividual diﬀerences and the
intra-individual diﬀerences. Our analysis reveals an average in-
traindividual Euclidean distance of 3.4 compared to 5.4 between
the individuals. This is in line with other observations that pro-
tein levels in plasma remain constant over the course of one year
and that each person has a unique proﬁle.
3.7. Comparison to Orthogonal Plasma Assays
Finally, we aimed to conﬁrm the data obtained by the selected
Ab pairs though using additional analyses. This assessment was
based on comparing our data with results from targeted plasma
MS analysis[15] and solution-based proximity extension assays
(PEA).[16] For above methods, we obtained data sets generated in
previous studies of the longitudinal sample analyzed in the appli-
cation phase (Fagerberg et al., unpublished). Using direct corre-
lation analysis as a proxy to determine the similarity between the
generated data sets, protein levels from 14 targets were studied.
Of the alternative methods, data for ten proteins only were avail-
able for PEA and for four proteins from MS only. As shown in
Table 4 and Figure 7A–D, correlations between our protein levels
and another aﬃnity-basedmethod, PEA, reached R2 = 0.6± 0.2
while correlations with peptide abundance from MS were R2 =
0.3± 0.2. This illustrates that it was possible to obtain supportive
evidence for some of the target proteins, but diﬀerences between
the assay types in terms of sensitivity and assay interference be-
tween the technologies may have contributed to a reduction in
concordance. It is worth noting that the assays were performed
in diﬀerent labs and at diﬀerent timepoints, too. When choosing
other capAbs of the SBAs than those shortlisted for the preferred
pairs, an additional set of ten capAbs were available to compare
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Table 4. Validation of antibody pair with orthogonal methods (PEA, MS).
Protein Assay 1 (SIA pair of interest) (capAb-detAb) Assay 2 Pearson’s R2
AFM HPA052437-HPA017006 HPA017006-HPA017006 0.93
HPA052437-HPA017006 MS 0.52
ANGPTL3 HPA038097-HPA072914 HPA054306-HPA072914 0.50
HPA038097-HPA072914 PEA 0.46
APOA4 HPA005149-HPA005149 MS 0.52
CCL16 HPA068091-HPA042909 HPA042909-HPA042909 0.81
HPA068091-HPA042909 HPA051577-HPA042909 0.94
HPA068091-HPA042909 PEA 0.63
CD5L HPA026432-HPA026432 MS 0.16
CFHR5 HPA072446-HPA072446 PEA 0.79
CHIT1 HPA010575-HPA010575 HPA010115-HPA010575 0.97
HPA010575-HPA010575 PEA 0.85
CPA1 HPA052215-HPA052215 PEA 0.85
CPN2 HPA004732-HPA004732 MS 0.12
EFEMP1 HPA071588-HPA070841 HPA062231-HPA070841 0.77
HPA071588-HPA070841 PEA 0.13
FGF21 HPA061286-HPA072401 PEA 0.73
IGFBP2 HPA077723-HPA004754 HPA004754-HPA004754 0.89
HPA077723-HPA004754 PEA 0.60
INHBC HPA071895-HPA050755 HPA057468-HPA050755 0.93
HPA071895-HPA050755 HPA050755-HPA050755 0.96
HPA071895-HPA050755 HPA020729-HPA050755 0.88
HPA071895-HPA050755 PEA 0.35
SPON2 HPA040170-HPA066095 PEA 0.36
Available orthogonal data n Average R2 ± SD
SIA (intra) 10 0.9 ± 0.1
PEA 10 0.6 ± 0.2
MS 4 0.3 ± 0.2
the data from the primaryAb pairs with. Since the data from these
assays were obtained from the same sample incubation and used
the same detAb, it was less surprising but reassuring to ﬁnd a
high correlation between the primary and additional Ab pairs of
R2 = 0.9 ± 0.1 (Table 4).
4. Discussion
This study describes a workﬂow based on a multiplexed bead-
based platform and high-quality reagent resources to systemati-
cally screen, select, and apply pairs of Abs for the quantiﬁcation of
secreted proteins in human plasma. Starting from 1791 unique
Ab pairs built on 624 unique Abs, two rounds of screening were
conducted on parallel dilution series of EDTA plasma and the re-
combinant full-length target protein.We found that 20%or 361 of
all possible pairs detected the recombinant as well as the plasma
protein in a concentration dependent manner. We applied a se-
lected set of 32 SIA pairs to study the protein levels in plasma
collected from 18 subjects every third month over 1 year and ﬁ-
nally conﬁrmed these ﬁndings by using orthogonal assays for 14
targets. For six of these, the Pearson correlation between the or-
thogonal assay and the validated SIA pair was R2 > 0.6.
Our study was based on the use of available HSP proteins and
HPA Abs. The polyclonal binders undergo a stringent quality
assessment for the use of immunoassays such as Western blot,
immunohistochemistry, and confocal microscopy. However,
the functionality in other types of assays and samples require
separate eﬀorts and we did not ﬁnd a direct link between
building functional SIA pairs with pre-assessing these binders
in Western blots on plasma (data not shown). Further to this, we
did not include aﬃnity reagents generated by other providers,
which may have limited us in providing larger number of assays
in the end. In addition, we estimate that many of the capAbs
that are currently part of “nonfunctional” pairs could indeed
enrich the target protein of interest, but the tested detAb was
not suitable in combination with these. We also acknowledge
the fact that polyclonal Abs need to be regenerated for extended
use and are therefore less suitable for clinical utility. However,
applying stringent validation criteria and generation of larger
batches may still open up these binders for large-scale studies
and exploratory research. In addition, identifying suitable
antigens from studies based on polyclonal Abs may stream-
line the development of monoclonal and recombinant binder
libraries.
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Figure 7. A–D) Comparison of assays for detecting in human plasma. Protein concentration achieved from the SIA pairs was compared with solution-
based proximity extension assays. The paired plots for ANGPTL3, CHIT1, CPA1, and FGF21 show the distribution of the data as histograms for each assay,
the R2 from the Pearson correlation between diﬀerent SIA pairs and PEA assays. For visualization and correlation, the SIA data was log2-transformed
and NPX values from PEA were used. The Abs used for the SIA pairs are described as capture-detection, and the numbers stated in the upper right-hand
corner refer to the R2 correlation values: For ANGPTL3 (A) and CHIT1 (B) data from two SIA pairs were compared to each other (R2 = 0.50 or 0.97)
and to data from PEA (R2 = 0.46 and 0.30 for ANGPTL3; R2 = 0.71 and 0.85 for CHIT1). For CPA1 (C) and FGF21 (D), data from one SIA pair were
compared to data from PEA (R2 = 0.85 or 0.73). The validated SIA pairs that were included to proﬁle the longitudinal samples are highlighted with “*.”
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Figure 7. Continued.
The proteins that we quantiﬁed here are important indicators
of health status relevant for diﬀerent diseases: FGF21 for exam-
ple is a known key regulator in lipid and glucose metabolism,
which is increased in conditions such as type 2 diabetes, obesity,
and nonalcoholic fatty liver disease.[24] CHIT1 serves as a neu-
roinﬂammatory marker and shows increased concentrations in
sALS (sporadic amyotrophic lateral sclerosis).[25] ER stress is hy-
pothesized to lead to hereditary pancreatitis may promote the de-
velopment of pancreatic ductal adenocarcinoma. CPA1 is among
the highest expressed genes in acinar cells, thus CPA1 pro-
teins are expected to cause more ER stress than lower expressed
pancreatic enzymes and are indicated to be associated not only
with pancreatic cancer development, but also its susceptibility.[26]
ANGPTL3 is a novel factor modulating the plasma lipopro-
tein metabolism[27] and may additionally contribute to uremic
dyslipidemia.[28] Plasma levels of NPPA have been described as
prognostic predictors in patients with chronic heart failure, but
are also known to reﬂect the severity of left ventricular hemody-
namic dysfunction.[29] It has been suggested that FGL1 plays a
role in liver protection and liver regeneration, but it also has the
potential to serve as a target for the treatment of gastric cancer
and to predict gastric cancer prognosis.[30] In addition, CCL16, a
human CC chemokine, has been shown to be diﬀerentially ex-
pressed in ovarian cancer.[31,32]
The study presented here uses pooled plasma collected from
nondiseased subjects. This sample source may have limited the
possibility to detect those proteins that increase with inﬂamma-
tion, infection, or other diseases. In addition, more assay opti-
mization may have been necessary to rescue some of those pairs
that detected their target protein but did not reveal signals above
background in plasma. It may further be necessary to choose
other, more sensitive detection systems and thereby sacriﬁcing
some of the SBA’s capabilities in terms of target and sample
throughput. Some Abs showed binding to other than their in-
tended targets once higher amounts of plasma (in particular 1:2).
These points at further optimization of the assays are needed in
terms of blocking agents and that not all Ab pairs are compatible
with another. Additionally, the apparent LOD and LLOQ levels
may increase once more complex buﬀer solutions are used.
To our current knowledge, this is one of the largest and ﬁrst
systematic study to screen for SIAs. We focused on the plasma
secretome, as plasma is an important sample for clinical routine
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analysis and a highly interesting source for searching for disease
related proteins. We assumed that the proteins secreted into the
blood stream remain detectable in solution when plasma is be-
ing prepared. In comparison to studying proteins in cell lysates,
proteins found in plasma do not require to be extracted, hence
the need to apply strong detergents can be omitted. However,
we acknowledge that proteins may precipitate or denature dur-
ing sample processing. Some proteins are known to be unstable
and degrade over time, hence the possibility to detect these de-
creases with the age of the sample.
In addition to expand our possibilities to measure proteins
actively secreted into blood, highly multiplexed immunoassays
as well as MS-based approaches require more targeted assays
to validate and quantify potential ﬁndings in larger number of
samples as well as using orthogonal methods. One advantage
of our SIA screening approach is that it provides a foundation
for the development of more sensitive assays in human plasma,
and it enables to build quantitative assays clinical routines, and
allows the transfer of these validated pairs of Abs onto other
immunoassay platforms or emerging technologies. It holds a
great value to expand this list of assays for the plasma secretome
to measure and quantify the plasma components of interest on a
protein level. Considering the targets included in our study, this
suggests that the detectability of proteins in plasma is predomi-
nantly depended on the interplay between the available reagents,
the technology, and protein stability. We are, however, well
aware that many other, such as the low abundant cytokines,[33]
require minimal sample dilutions to detect proteins of pg mL–1
concentrations, and we suggest to include necessary controls
and considerate elevated and unspeciﬁc background binding.
In summary, multiplexed bead arrays were used to screen for
functional Ab pairs in proteins and plasma samples. With a suc-
cess rate of 20%, we found that investing at least three diﬀerent
Abs per target protein and assessing diﬀerent capture–detection
combinations was necessary to obtain Ab pairs for protein quan-
tiﬁcation. While further assay optimization, additional Abs, and
target-centric studies will be needed to assess the utility of these
Ab pairs, we could not observe a trend toward any binding-site
preference for building functional assays for secreted proteins.
Considering the need to generate renewable reagents for ex-
tended use, our study provides valuable leads on selecting and
building Ab pairs even with other reagents than those used here.
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